Cytonics Announces Completion Of Enrollment For Phase 1 Clinical Study Evaluating CYT ...
Cytonics completes enrollment for Phase 1 study of CYT-108, a recombinant protease inhibitor for knee osteoarthritis, with no drug-related adverse events reported. Top-line results expected in Q2 2025.
Reference News
Cytonics concludes subject enrolment in Phase I trial of CYT-108, a recombinant alpha-2-macroglobulin for osteoarthritis of the knee, designed to assess safety and efficacy via intra-articular injection, with no drug-related adverse events reported.
Cytonics completes enrollment for Phase 1 study of CYT-108, a recombinant protease inhibitor for knee osteoarthritis, with no drug-related adverse events reported. Top-line results expected in Q2 2025.
Cytonics completes enrollment for Phase 1 study of CYT-108, a recombinant alpha-2-macroglobulin for osteoarthritis, with no drug-related adverse events reported.